⌕
Eton Pharmaceuticals · ETON · Nasdaq
Tenet 47 · Mixed
Compare
$63.88−0.08%At closeTenet 47 · Mixed
$63.88−0.05 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Eton Pharmaceuticals (ETON) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ETON's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 08:50 ET
Eton Pharmaceuticals: The Commercial Model Is Finally Scaling

Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA ma…

ETON −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 05:30 ET
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.…

ETON −0.1% todayRead at source ↗
● MarketBeatNov 6, 2026 · 01:16 ET
Eton Pharmaceuticals Q3 Earnings Call Highlights

Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product …

ETON −0.1% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 21:04 ET
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript…

ETON −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 21:02 ET
Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results

Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully d…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability

Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% i…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London

DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…

ETON −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 13:01 ET
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?

Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…

ETON −0.1% todayRead at source ↗
● Defense WorldOct 26, 2026 · 04:57 ET
Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The …

ETON −0.1% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

ETON −0.1% todayRead at source ↗
● Defense WorldOct 8, 2026 · 04:15 ET
Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)

Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based…

ETON −0.1% todayRead at source ↗
● Zacks Investment ResearchOct 7, 2026 · 13:11 ET
ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireSep 28, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d…

ETON −0.1% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:29 ET
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Price Target of $67.50 According to Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ: ETON - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. Two investment …

ETON −0.1% todayRead at source ↗
● Defense WorldSep 2, 2026 · 03:50 ET
Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETON

Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission…

ETON −0.1% todayRead at source ↗
● Defense WorldAug 31, 2026 · 04:21 ET
BlackRock Inc. Invests $68.63 Million in Eton Pharmaceuticals, Inc. $ETON

BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833…

ETON −0.1% todayRead at source ↗
● Defense WorldAug 30, 2026 · 04:30 ET
Eton Pharmaceuticals, Inc. $ETON Stock Holdings Increased by Bank of America Corp DE

Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Co…

ETON −0.1% todayRead at source ↗
● Defense WorldAug 28, 2026 · 03:59 ET
Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON

Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The inst…

ETON −0.1% todayRead at source ↗
● GlobeNewsWireAug 27, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di…

ETON −0.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ETON · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.